BCL6 and chronic myelogenous leukemia, BCR-ABL1 positive: Increased expression of BCL6 in chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) has been shown to protect leukemic cells from chemotherapy induced DNA damage through the repression of p53 induced apoptosis [30, 31].